BDSI opioid dependence drug on track for midsummer FDA filing
Raleigh, N.C. —
The Raleigh company announced the progress following what BDSI described as “a positive” meeting with the Food and Drug Administration regarding the company’s currently experimental treatment.
Bunavail uses BDSI’s drug delivery technology to administer the buprenorphine, a drug used for opioid dependence. BDSI’s patented technology delivers a drug via a soluble film that is placed on the inside of the cheek. BDSI aims to challenge market leader Reckitt Benckiser, whose Suboxone administers buprenorphine via a small piece of disssolvable film placed under the tongue.
More than 2 million people in the United States suffer from opioid dependence. RB claims that Suboxone has given it 64 percent of the market to treat such patients. Suboxone generated nearly $1.5 billion in 2012 revenue, according to data compiled by drugs.com. BDSI has said among Bunavail’s advantages is offering treatment without the unpleasant taste that is a complaint of some patients treated with Suboxone. BDSI believes it can pick up as much as $250 million in sales from this market.
Please Log In to add a comment.
Best of TechWire Insider
- Fighting hospital infections: A Durham nurse's dream produces the GoGown
- From photos to out-of-this-world art: Raleigh firm's software transforms images
- LabCorp expands gene tests for cancer - but don't confuse these with 23andMe
- ChannelAdvisor: Mobile cuts deeply into PC share of online shopping
- Inside Appia's latest funding deal: Debt beats dilution
- Can Barley's bark win Super Bowl gold for Durham startup?
- Tech guru Mossberg changes gears, praises Republic Wireless
- Survey explodes myth of the poor VC-backed entrepreneur
- Analyze this: SAS steps up education commitment with Teradata deal
- Web Foundation report reflects concerns about US security state